Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Related Keywords

China ,Guangzhou ,Guangdong ,Shanghai ,Suzhou ,Jiangsu ,Yu Shen ,Boston ,Massachusetts ,United States ,Beijing ,Houston ,Texas ,Miao Zhang ,Shaanxi ,Jian Zhang ,Hangzhou ,Zhejiang ,San Francisco ,California ,Lin Shen ,Changsong Qi ,Nashaty Gabrail ,Chuan Qi ,Jianming Wang ,Zhenzhong Xia ,Li Xu ,Xueming Qian ,Los Angeles ,Michael Shi ,Jifang Gong ,Weijian Guo ,Clinical Development Centers ,Transcenta Holding ,International Gastric Cancer Congress ,Drug Administration ,Product Development Center ,Translational Research Center ,Group Headquarters ,Transcenta Holding Limited ,Business Development ,Transcenta Immune Tolerance Breaking Technology ,Phasei Clinical Trial ,Locally Advanced ,Metastatic Solid ,Phasei Study ,Pancreatic Cancer ,Orphan Drug Designation ,Immune Tolerance Breaking Technology ,Manufacturing Facility ,External Partnering Center ,Suzhou Industrial ,